Red blood cells and platelets (RBC and PLT)

Red blood cells (erythrocytes) and platelets (thrombocytes) are the primary non-leukocyte cellular components of human blood, both originating from hematopoietic stem cells in the bone marrow [1, 2]. Red blood cells are specialized for gas transport, utilizing hemoglobin to carry oxygen from the lungs to tissues and facilitate the transport of carbon dioxide back to the lungs [1]. Platelets are small, discoid cell fragments that play a critical role in primary hemostasis by adhering to damaged vascular endothelium and aggregating to form a platelet plug [2]. While these are distinct cell types rather than individual molecular targets, they are the focus of numerous therapeutic interventions. For instance, antiplatelet agents like aspirin and clopidogrel target specific enzymes or receptors on platelets to prevent arterial thrombosis [2]. Conversely, red blood cell function and production are modulated by agents such as erythropoietin for anemia or hydroxyurea for sickle cell disease [1, 3]. Pathologies involving these cells include various forms of anemia, polycythemia, thrombocytopenia, and thrombotic disorders [1, 2]. Monitoring these cells is essential in clinical practice, often through a complete blood count which measures parameters like hemoglobin levels and platelet counts [4].

Other names

Erythrocytes and thrombocytesRed cells and plateletsBlood cells (non-leukocyte)

Drugs targeting these cells act through various molecular mechanisms: antiplatelet agents inhibit platelet aggregation by blocking the COX-1 enzyme (aspirin) or the P2Y12 receptor (clopidogrel) [2]; erythropoiesis-stimulating agents activate the erythropoietin receptor to increase red blood cell production [1]; and fetal hemoglobin inducers like hydroxyurea reduce the polymerization of sickle hemoglobin in red blood cells [3].